BioPharmSignal logoBioPharmSignal

Biotech News

Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

Mineralys Therapeutics (MLYS)Mineralys TherapeuticsClinical readout

MLYS (MLYS) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is mlys.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

MLYSMineralys Therapeutics2026-05-30 15:15 EST

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

MLYSMineralys Therapeutics2026-03-09 20:30 EST

Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results

VKTXViking Therapeutics2026-05-12 11:05 EST

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

VKTXViking Therapeutics2026-03-26 11:05 EST

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

ALGSAligos Therapeutics2026-01-21 13:00 EST

Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates

ALGSAligos Therapeutics2026-05-27 06:30 EST

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

CVRXCVRx2026-05-04 20:30 EST

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

NAMSNewAmsterdam Pharma2026-07-24 12:00 EST

NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

MNKDMannKind2026-06-03 10:05 EST

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

CVRXCVRx2026-01-22 21:05 EST

CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

View all latest news

Mineralys Therapeutics

Mineralys Therapeutics is a cardiometabolic company focused on aldosterone biology and hypertension-related opportunities. Its story is tied to differentiating a novel mechanism in a large market.

Recent company news

MLYSMineralys Therapeutics2026-07-27 20:01 EST

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

MLYSMineralys Therapeutics2026-06-14 14:00 EST

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

MLYSMineralys Therapeutics2026-06-08 20:05 EST

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

MLYSMineralys Therapeutics2026-06-08 11:00 EST

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)

MLYSMineralys Therapeutics2026-06-03 10:05 EST

Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

Stock data

Close
27.21 USD
Market cap
2.38B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States